Lineage Cell Therapeutics Inc (AMEX: LCTX) on Friday, plunged -4.17% from the previous trading day, before settling in for the closing price of $1.20. Within the past 52 weeks, LCTX’s price has moved between $0.84 and $1.61.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 119.78% over the last five years. The company achieved an average annual earnings per share of 5.56%. With a float of $187.49 million, this company’s outstanding shares have now reached $188.53 million.
The firm has a total of 75 workers. Let’s measure their productivity.
Lineage Cell Therapeutics Inc (LCTX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Lineage Cell Therapeutics Inc is 0.55%, while institutional ownership is 48.05%. The most recent insider transaction that took place on Feb 08 ’24, was worth 100,001. In this transaction Director of this company bought 96,155 shares at a rate of $1.04, taking the stock ownership to the 158,801 shares. Before that another transaction happened on Feb 06 ’24, when Company’s Director bought 6,730,770 for $1.04, making the entire transaction worth $7,000,001. This insider now owns 41,666,255 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 46.57 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 5.56% per share during the next fiscal year.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Lineage Cell Therapeutics Inc (LCTX) is currently performing well based on its current performance indicators. A quick ratio of 2.14 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 24.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.12, a number that is poised to hit -0.04 in the next quarter and is forecasted to reach -0.12 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Analysing the last 5-days average volume posted by the [Lineage Cell Therapeutics Inc, LCTX], we can find that recorded value of 1.18 million was better than the volume posted last year of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 22.65%. Additionally, its Average True Range was 0.12.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 40.15%, which indicates a significant increase from 6.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.24% in the past 14 days, which was higher than the 83.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2164, while its 200-day Moving Average is $1.2058. Now, the first resistance to watch is $1.2133. This is followed by the second major resistance level at $1.2767. The third major resistance level sits at $1.3233. If the price goes on to break the first support level at $1.1033, it is likely to go to the next support level at $1.0567. Should the price break the second support level, the third support level stands at $0.9933.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
Market capitalization of the company is 216.81 million based on 188,534K outstanding shares. Right now, sales total 8,950 K and income totals -21,490 K. The company made 2,090 K in profit during its latest quarter, and -4,780 K in sales during its previous quarter.
